Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis

Abstract

The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compositions comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent. In the invention the 2,5-dihydroxybenzene sulfonic acid compounds or pharmaceutically acceptable salts thereof are 2,5-dihydroxybenzene sulfonic acid, calcium 2,5-dihydroxybenzenesulfonate, potassium 2,5-dihydroxybenzenesulfonate, magnesium 2,5-dihydroxybenzenesulfonate and diethylamine 2,5-dihydroxybenzenesulfonate.

1 . A method for treating a skin cancer; treating cancer of an organ; treating leukemia; improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salts thereof:
 wherein the compound of Formula (I) is:   
       
         
           
           
               
               
           
         
         wherein: 
         X is a hydrogen, an organic cation or an inorganic cation; 
         n is an integer from 1 to 2; and 
         m is an integer from 1 to 2. 
       
     
     
         2 . The method of  claim 1 , further comprising administering a pharmaceutically acceptable carrier. 
     
     
         3 . The method of  claim 1 , wherein the compound of Formula (I) is selected from the group consisting of:
 2,5-dihydroxybenzene sulfonic acid;   calcium 2,5-dihydroxybenzenesulfonate;   potassium 2,5-dihydroxybenzenesulfonate;   magnesium 2,5-dihydroxybenzenesulfonate; and   diethylamine 2,5-dihydroxybenzenesulfonate.   
     
     
         4 . The method of  claim 1 , further comprising at least one therapeutic agent. 
     
     
         5 . The method of  claim 4 , wherein the therapeutic agent is a chemotherapeutic agent, a steroid, a retinoid, an antimicrobial compound, an antioxidant, an anti-inflammatory compound, a NMDA receptor antagonist, an endothelin antagonist, an immunomodulating agent, a vitamin D analogue, salicylic acid, or a combination of two or more thereof. 
     
     
         6 . The method of  claim 5 , wherein the therapeutic agent is selected from the group consisting of a chemotherapeutic agent, a steroid, an antimicrobial compound, an antioxidant, an anti-inflammatory compound, a NMDA receptor antagonist, an endothelin antagonist and an immunomodulating agent. 
     
     
         7 . The method of  claim 1 , wherein the skin cancer is basal cell cacinoma, squamous cell carcinoma, a melanoma, a keratoacanthoma, an actinic keratosis, a Bowen's disease verrucae, sarcomas orangiosarcoma. 
     
     
         8 . The method of  claim 1 , wherein the compound of Formula (I) is administered orally, bucally, parenterally, by inhalation, by topical application or rectally. 
     
     
         9 . A method for treating rosacea in a patient in need thereof comprising topically administering to the patient a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salts thereof:
 wherein the compound of Formula (I) is:   
       
         
           
           
               
               
           
         
         wherein: 
         X is a hydrogen, an organic cation or an inorganic cation; 
         n is an integer from 1 to 2; and 
         m is an integer from 1 to 2. 
       
     
     
         10 . The method of  claim 9 , further comprising administering a pharmaceutically acceptable carrier. 
     
     
         11 . The method of  claim 9 , wherein the compound of Formula (I) is selected from the group consisting of:
 2,5-dihydroxybenzene sulfonic acid;   calcium 2,5-dihydroxybenzenesulfonate;   potassium 2,5-dihydroxybenzenesulfonate;   magnesium 2,5-dihydroxybenzenesulfonate; and   diethylamine 2,5-dihydroxybenzenesulfonate.   
     
     
         12 . The method of  claim 9 , further comprising at least one therapeutic agent. 
     
     
         13 . The method of  claim 12 , wherein the therapeutic agent is a chemotherapeutic agent, a steroid, a retinoid, an antimicrobial compound, an antioxidant, an anti-inflammatory compound, a NMDA receptor antagonist, an endothelin antagonist, an immunomodulating agent, a vitamin D analogue, salicylic acid, or a combination of two or more thereof. 
     
     
         14 . The method of  claim 13 , wherein the therapeutic agent is selected from the group consisting of a steroid, a retinoid, an antimicrobial compound, an antioxidant, an anti-inflammatory compound, a vitamin D analogue and salicylic acid. 
     
     
         15 . A method for treating psoriasis in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salts thereof and at least one therapeutic agent:
 wherein the compound of Formula (I) is:   
       
         
           
           
               
               
           
         
         wherein: 
         X is a hydrogen, an organic cation or an inorganic cation; 
         n is an integer from 1 to 2; and 
         m is an integer from 1 to 2. 
       
     
     
         16 . The method of  claim 15 , further comprising administering a pharmaceutically acceptable carrier. 
     
     
         17 . The method of  claim 15 , wherein the compound of Formula (I) is selected from the group consisting of:
 2,5-dihydroxybenzene sulfonic acid;   calcium 2,5-dihydroxybenzenesulfonate;   potassium 2,5-dihydroxybenzenesulfonate;   magnesium 2,5-dihydroxybenzenesulfonate; and   diethylamine 2,5-dihydroxybenzenesulfonate.   
     
     
         18 . The method of  claim 15 , wherein the therapeutic agent is a chemotherapeutic agent, a steroid, a retinoid, an antimicrobial compound, an antioxidant, an anti-inflammatory compound, a NMDA receptor antagonist, an endothelin antagonist, an immunomodulating agent, a vitamin D analogue, salicylic acid, or a combination of two or more thereof. 
     
     
         19 . The method of  claim 18 , wherein the therapeutic agent is selected from the group consisting of a steroid, a retinoid, an antimicrobial compound, an antioxidant, an anti-inflammatory compound, a Vitamin D analogue and salicylic acid. 
     
     
         20 . The method of  claim 15 , wherein the compound of Formula (I) and the therapeutic agent are administered orally, bucally, parenterally, by inhalation, by topical application or rectally.